Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement
- PMID: 22964825
- DOI: 10.7326/0003-4819-157-11-201212040-00539
Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement
Abstract
Description: Reaffirmation of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for ovarian cancer.
Methods: A 2008 review of the literature commissioned by the USPSTF revealed no new evidence about the benefits of screening for ovarian cancer but provided some new data about observed harms of screening. A bridge search to 2011 focused on evidence from randomized, controlled trials.
Population: This recommendation applies to asymptomatic women. It does not apply to women with known genetic mutations that increase their risk for ovarian cancer (for example, BRCA mutations).
Recommendation: The USPSTF recommends against screening for ovarian cancer in women (D recommendation).
Summary for patients in
-
Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.Ann Intern Med. 2012 Dec 18;157(12):I-56. doi: 10.7326/0003-4819-157-11-201212040-00540. Ann Intern Med. 2012. PMID: 23362519 No abstract available.
Similar articles
-
Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.Ann Intern Med. 2012 Dec 18;157(12):I-56. doi: 10.7326/0003-4819-157-11-201212040-00540. Ann Intern Med. 2012. PMID: 23362519 No abstract available.
-
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2014 Feb 18;160(4):271-81. doi: 10.7326/M13-2747. Ann Intern Med. 2014. PMID: 24366376
-
Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2012 Jun 19;156(12):880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424. Ann Intern Med. 2012. PMID: 22711081
-
Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421. JAMA. 2018. PMID: 29450530 Review.
-
Clinical practice. Screening for ovarian cancer.N Engl J Med. 2009 Jul 9;361(2):170-7. doi: 10.1056/NEJMcp0901926. N Engl J Med. 2009. PMID: 19587342 Review. No abstract available.
Cited by
-
The 2020 US cancer screening deficit and the timing of adults' most recent screen: a population-based cross-sectional study.Fam Med Community Health. 2023 Sep;11(3):e001893. doi: 10.1136/fmch-2022-001893. Fam Med Community Health. 2023. PMID: 37730268 Free PMC article.
-
BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression.Mol Cell Biochem. 2022 May;477(5):1541-1553. doi: 10.1007/s11010-022-04389-1. Epub 2022 Feb 19. Mol Cell Biochem. 2022. PMID: 35184257
-
Increased expression of KPNA2 predicts unfavorable prognosis in ovarian cancer patients, possibly by targeting KIF4A signaling.J Ovarian Res. 2021 May 25;14(1):71. doi: 10.1186/s13048-021-00818-9. J Ovarian Res. 2021. PMID: 34034774 Free PMC article.
-
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.Cancers (Basel). 2020 Dec 11;12(12):3734. doi: 10.3390/cancers12123734. Cancers (Basel). 2020. PMID: 33322608 Free PMC article.
-
Ovarian Cancer: Tumor-Specific Urinary Micro-Peptides Profiling as Potential Biomarkers for Early Diagnosis.Proteomes. 2020 Oct 29;8(4):32. doi: 10.3390/proteomes8040032. Proteomes. 2020. PMID: 33137912 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
